Nivolumab in Kombination mit Ipilimumab vs. Sunitinib-Monotherapie – SUNNIFORECAST – AN 41/16 der AUO
Crossref DOI link: https://doi.org/10.1007/s00120-017-0397-1
Published Online: 2017-05-23
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rexer, H.
Steiner, T.
Bergmann, L.
License valid from 2017-05-23